-
STAT News – Biotech2 weeks agoThe impact of NIH restrictions on foreign institutions
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. We’re down to the final four...
-
STAT News – Biotech2 weeks agoSTAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send...
-
STAT News – Biotech2 weeks agoSTAT+: Pharmalittle: We’re reading about Novo Nordisk boosting consumer focus, FDA approving a gene therapy, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to...
-
STAT News – Biotech2 weeks agoAs political pressure mounts, medical school accreditor drops requirement to teach about health equity
The leading medical school accreditation body in the U.S. has removed language from its standards that had required schools it validates to teach about health inequities. ...
-
STAT News – Biotech2 weeks agoDecades after Vietnam War, research links Agent Orange exposure to MDS blood cancer
Decades after the Vietnam War, hematologist-oncologist Mikkael Sekeres began seeing veterans in his clinic with myelodysplastic syndromes, a group of blood cancers known as MDS. Many...
-
STAT News – Biotech2 weeks agoSTAT+: Trump administration says home care fraud is ‘rampant.’ What do the data show?
In February, the U.S. DOGE Service released a gigantic dataset showing Medicaid provider spending from every month from 2018 to 2024. Social media buzzed with eye-popping...
-
STAT News – Biotech2 weeks agoOpinion: Future physicians need more nutrition education — but not of the MAHA variety
After decades of research, there is little doubt that nutrition plays a critical role in promoting health across the lifespan. This is especially true among vulnerable...
BioNTech to shutter Singapore HQ after ‘comprehensive review’
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
